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Background: Molecular typing is essential for inferring genetic relatedness between
bacterial pathogens. In this study, we applied whole genome sequencing (WGS) for rapid
prediction of sequence type and antibiotic resistance for invasive pneumococcal isolates.
Methods: 240 isolates from adults (≥50 years old) in Ontario, Canada during 2009
to 2013 were subjected to WGS. Sequence type, antibiotic susceptibility and resistance
were predicted directly from short reads. Emerging non-vaccine serotype 22F was further
characterized by WGS.
Results: Sequence type was successfully determined for 98.3% of isolates. The
overall sensitivity and specificity for antibiotic resistance prediction were 95 and
100% respectively, compared to standard susceptibility testing methods. WGS-based
phylogeny divided emerging 22F (ST433) strains into two distinct clades: clade A
harboring a 23 kb-prophage and anti-phage PhD/Doc system and clade B with
virulence-related proteases. Five isolates in clade A developed macrolide resistance via
5.1 kb mega element recombination (encoding mefE and msrD), while one isolate in
clade B displayed quinolone resistance via a gyrA mutation.
Conclusions: WGS is valuable for routine surveillance of pneumococcal clinical isolates
and facilitates prediction of genotype and antibiotic resistance. The emergence of 22F
in Ontario in the post-vaccine era and evidence of evolution and divergence of the 22F
population warrants heightened pneumococcal molecular surveillance.
Keywords: invasive pneumococcal disease, whole-genome sequencing, emerging 22F, antibiotic resistance
prediction, genomic diversification
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INTRODUCTION
Invasive pneumococcal diseases (IPD) such as septicaemia and
meningitis caused by Streptococcus pneumoniae result in a
heavy burden of disease among children and adults worldwide
(Ausina et al., 1988; O’Brien et al., 2007). After widespread
implementation in 2002 of the 7-valent pneumococcal conjugate
vaccine (PCV7, covering serotypes 4, 6B, 9V, 14, 18C, 19F,
and 23F) in Canadian children, the incidence of IPD due to
PCV7 serotypes decreased significantly in all age groups within
the Canadian population (Kellner et al., 2009). In 2010 the
new PCV13 vaccine (PCV7 serotypes plus 1, 3, 5, 6A, 7F, and
19A) replaced the PCV7 vaccine for routine immunization of
children (Desai et al., 2010). Shortly after implementation of
PCV13 in Canada, the number of IPD cases due to vaccine-
associated serotypes such as 19A and 7F declined (Deng et al.,
2015). However, the concurrent increase of IPD due to non-
vaccine serotypes 22F, 15A, 33F, and 35B post-introduction
of PCV13 has become a concern to clinicians (Deng et al.,
2015; Golden et al., 2015; Duvvuri et al., 2016). In addition
to use in children, the PCV13 vaccine was also approved by
Canadian health authorities in 2012 for use among adults 50 years
and older for the prevention of IPD (An Advisory Committee
Statement (ACS), 2013). Currently it is also recommended for
immunocompromised adults aged ≥ 18 years with high risk of
IPD (An Advisory Committee Statement (ACS), 2013; Tomczyk
et al., 2014).
Streptococcus pneumoniae is naturally competent, so it can
uptake DNA from environment and undergo horizontal gene
transfer between strains. Some recombination events such as
deletions, insertions and inversions are frequently observed
in the pneumococcal genome. In nature, horizontal gene
transfer facilitates bacterial evolution, providing S. pneumoniae
with easy access to crucial resistance genes and/or virulence
factors. A recent analysis of the whole genome sequences
of 240 Pneumococcal Molecular Epidemiological Network
(PMEN1) pneumococcal strains revealed an exceptionally high
recombination/mutation ratio of 7.2, and an average of 72
single nucleotide polymorphisms (SNPs) per recombination site
(Croucher et al., 2011).
Molecular typing of Streptococcus pneumoniae is important
for delineating genetic structure of bacterial populations and
useful for inferring evolutionary relationships between isolates.
For years, pulse-field gel electrophoresis (PFGE) that is based
on motility variations of restriction fragments was considered
the “gold standard” for subtyping of bacterial strains (Tenover
et al., 1995). However, this method is technically demanding and
time-consuming, and is thus not widely used for epidemiological
surveillance. Multi-locus sequence typing (MLST) that measures
DNA sequence variations for multiple housekeeping genes
gradually replaced PFGE as a popular typing tool in the
21st century (Maiden et al., 1998). However, MLST has its
shortcomings, as it is time-consuming, labor intensive and
has higher cost than PFGE (Sabat et al., 2013). Recently,
next-generation whole genome sequencing (WGS) has become
a powerful and attractive tool for rapid typing of bacterial
isolates, such as for E. coli (Joensen et al., 2014) and group
A streptococcus (Athey et al., 2014). In addition, WGS has
been evaluated for rapid prediction of drug susceptibility and
resistance in Mycobacterium tuberculosis (Walker et al., 2015)
and Staphylococcus aureus isolates (Gordon et al., 2014). With
the cost of WGS continuing to decline (to a price close to or
lower thanMLST), it has the potential of replacing currently used
typing methods for clinical isolates in the near future.
To date, MLST remains the primary method for large-
scale typing of S. pneumoniae in the clinical laboratory. In
this surveillance study, we employed high-throughput whole-
genome sequencing for rapid prediction of MLST and antibiotic
resistance in silico and further characterization of emerging non-
vaccine serotypes of S. pneumoniae following the introduction of
PCV13 in Ontario, Canada.
MATERIALS AND METHODS
Clinical Pneumococcal Isolates and
Antimicrobial Susceptibility Testing
Invasive S. pneumoniae isolates (1956 in total, approximately
400 isolates per year) were collected from older adults
(≥50 years of age) in Ontario, Canada between 2009 and
2013. Submission of IPD isolates to Public Health Ontario
Laboratories (PHOL) for further evaluation is encouraged but
not mandatory. Geographic mapping of pneumococcal disease
cases in Ontario older adults during 2009–2013 was done with
geographic information system software QGIS (Version 2.8,
http://www.qgis.org/). First 3 digits of postcode of each patient’s
residential address were used for the geographic mapping.
Clinical isolates were recovered from sterile sites (including
blood, cerebrospinal fluid and pleural fluid) and sent to the
National Microbiology Laboratory (NML) in Winnipeg, Canada
for serotyping using the Quellung reaction. Broth microdilution
panels (Thermo Scientific, Waltham, MA, USA) were used for
antimicrobial susceptibility testing for penicillin, erythromycin,
clindamycin, fluoroquinolones, tetracycline, and cephalosporins.
Minimum inhibitory concentrations (MICs) for each antibiotic
were determined according to 2015 Clinical and Laboratory
Standards Institute (CLSI) guidelines.
Strain Selection for Whole Genome
Sequencing
We randomly selected 48 strains per year from 2009 to 2013 (240
isolates in total) from all available isolates in our S. pneumoniae
database. The number of isolates selected per serotype was
proportional to all isolates in that year, with the exclusion of
rare serotypes that had a frequency <1.5%. Illumina multiplex
sequencing strategy was used for sequencing the 240 isolates
using high-throughput processing. Genomic DNA of clinical
isolates was extracted using QIAamp DNA mini kits (Qiagen,
Germany). A library of multiplexed samples (96 indexes for
Hiseq and 12-24 indexes for Miseq) was prepared according to
standard protocols using the Nextera XT kit. Genomic libraries
of 192 samples were sequenced using Illumina Hiseq 2500 (100
bp paired end, Illumina, San Diego, USA), 44 samples were
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sequenced using Illumina Miseq (150 bp paired end), and 4
samples were not sequenced due to poor quality of library.
Prediction of MLST Type and Antibiotic
Resistance from Short Reads
The MLST sequence type was determined from short
reads for each isolate using SRST2 software (Inouye et al.,
2012). Genetic determinants for resistance to antibiotics
including chloramphenicol, macrolides, clindamycin and
tetracycline were deduced from short reads using SRST2
software by comparison with a database of resistance genes
(https://github.com/katholt/srst2). The predicted susceptibilities
by whole-genome sequencing were compared with phenotypic
drug susceptibility test results. When there was a mismatch
between phenotype and genomic prediction, phenotypic drug
susceptibility tests were repeated for those isolates. Two types of
errors were defined for the susceptibility portion of this study: a
very major error (VME) referred to a susceptible genotype with
a resistant phenotype, and a major error (ME) was defined as a
resistant genotype with a susceptible phenotype.
Genomic Characterization of Emerging
Non-Vaccine Serotype 22F
Genomes for 22F isolates were assembled de novo using Velvet
1.2.07 (Zerbino and Birney, 2008) and VelvetOptimiser (mean
coverage 208x). The draft genomes had an average of 333 contigs
and mean N50 of 61885 bp. The draft genomes were annotated
automatically with the RAST pipeline (rast.nmpdr.org). The draft
genomes of 22F have been deposited at DDBJ/EMBL/GenBank
under accession MLG(H-Z)00000000 and MLH(A-F)00000000.
Raw Illumina sequences of 236 isolates have been deposited at
SRA/NCBI under accession SRR3211687-729, SRR5011653-846.
Core genomes and accessory genomes of 22F were predicted
using Pan-Genomes Analysis Pipeline (PGAP) (Zhao et al., 2012)
that utilizes BLAST command line tools (NCBI), InParanoid
(O’Brien et al., 2005) andMultiParanoid (Alexeyenko et al., 2006)
software. The core genes shared by all 22F isolates were retrieved
and concatenated to make a “core” genome. MEGA5 (Tamura
et al., 2011) was used to align these core genome sequences and
to visualize single nucleotide polymorphism (SNP) variants. The
genome sequence alignments were imported into BratNextGen
(Marttinen et al., 2012) to infer regions of recombination and
for clustering analysis (grouping strains into subclusters). Gaps
and SNPs due to recombination were removed. The core genome
alignment file of 22F isolates was uploaded to CIPRES server
(www.phylo.org) for phylogenetic analysis. A phylogenetic tree
was constructed with RAxML (Stamatakis, 2014) using a GTR
model with a gamma correction for site rate variation. The
online tool, Interactive Tree of Life (Letunic and Bork, 2011)
was used for manipulation of phylogenetic trees. For comparative
genomic analysis, the accessory genomes of different groups (e.g.,
drug-resistant and susceptible isolates) of 22F were compared in
order to identify genetic features unique to any identified groups.
Z-test was used to predict significance of difference between the
proportions of strains in the two groups possessing a gene of
interest. P < 0.01 was considered statistically significant.
Statistical Tests
Chi-square test was used to determine the statistical difference
between the proportions of emerging serotypes (i.e., 22F) relative
to total isolates in each year between 2009 and 2013 (5
proportions compared using 2 × 5 contingency table). P <
0.05 was considered significant and a simple Z-test was used
to compare a pair of proportions (P < 0.05 is considered
significant).
RESULTS
Emergence of Non-PCV13 Serotypes
Post-Vaccination
Although, IPD isolates were voluntarily submitted to PHOL
from regional health units, distribution map of clinical samples
indicated a good representation of geographic regions in the
province of Ontario (Figure S1). Overall, during 2009–2013 IPD
cases in older adults (≥50 years of age) due to PCV13 serotypes
showed the trend of decline (chi-square test p< 0.01 between five
ratios), while IPDs due to non-PCV13 serotypes had the trend
of increase (chi-square test p < 0.01) (Figure 1). Non-PCV13
serotype 22F increased from 8.5% in 2009 to 14.5% in 2013 (p
< 0.01 for chi-square test, and p = 0.0061 bewteen 2009 and
2013) (Figure 2). In 2013, serotype 22F surpassed 19A and 7F,
and became the most common S. pneumoniae serotype identified
among IPD isolates from Ontario adults.
Sequence Type Prediction In silico and
Clonal Lineage Analysis
WGS was performed on a total of 236 IPD isolates (48 isolates
per year, with four strains excluded due to extremely low
concentrations of DNA following library preparation). MLST
sequence type was successfully predicted from Illumina short
reads directly for 232 strains, giving a success rate of 98.3%
(232/236). The four isolates that failed MLST prediction had
low sequence coverage (less than 10, ranging from 2 to 8). A
FIGURE 1 | Proportion of Streptococcus pneumoniae isolates causing
IPD among older adults (≥50 years of age) expressing PCV13 (1, 3, 4, 5,
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and non-PCV13 serotypes in
Ontario, Canada, during 2009–2013.
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FIGURE 2 | Serotype changes over time in IPD among older adults (≥50 years of age) in Ontario, Canada from 2009 to 2013. Serotype 22F increased
significantly after introduction of PCV13 (p < 0.01) between 2009 and 2013, and became most prevalent in 2013.
total of 90 different sequence types (ST) were identified and
these STs could be further divided into 17 clonal groups and
39 singletons (individual STs) through eBURST analysis. The
emerging post-PCV13 serotype 22F was exclusively associated
with clonal complex CC433 that include ST433 (25/26, 96%) and
ST4533 (1/26, 4%) a single allele variant of ST433. CC63, CC66
and CC100 were the major (>80%) CCs identified among 15A,
9N, and 33F, respectively (Table 1).
In silico Antibiotic Resistance Prediction
and Comparison with Phenotypic
Resistance Testing
The presence of acquired genes (Table S1 in supplementary
material) including cat, mefA, msrD, ermB, and tetM that are
associated with phenotypic resistance was predicted directly from
short reads for the IPD isolates sequenced. 226 (95.8%) isolates
had complete concordance between genotype and phenotype for
the antimicrobial agents tested. The remaining 10 isolates had
a total of 11 discrepancies between genotype and phenotype
(Table S2 in supplementary material). Repeated susceptibility
testing for the isolates with genotype/phenotype mismatches
reduced the number of discrepancies from 11 to 7, giving a
revised concordance rate of 97%. There were five very major
errors (0.55% VME rate) and two major errors (0.22% ME rate)
for antibiotic resistance prediction of S. pneumoniae isolates.
The overall sensitivity and specificity for predicting phenotypic
resistance to the antimicrobials tested using genomic data were
95% (95% CI, 90 to 97%), and 100% (95% CI, 99 to 100%),
respectively (Table 2).
Phylogenetic Analysis of 22F Reveals Two
Divergent Subpopulations
Of 26 serotype 22F isolates, 25 (96%) belonged to the same
sequence type, ST433. Core genome alignment (1581 genes) of
TABLE 1 | Sequence type composition of most common pneumococcal
serotypes causing IPD among older patients (≥50 years old) in Ontario,
Canada during 2009–2013.
Serotype Sequence type composition
22F CC433 (96%, ST433, 4%, SLV*/4553)
19A CC199 (36%, ST199, SLV/677/3976/2344), CC695 (36%, ST695,
SLV/8323), CC416 (12%, ST416, SLV/2343), ST320 (4%), ST63 (4%),
ST1201 (4%), ST5034 (4%)
7F CC191 (93%, ST191, 7%, SLV/9363/novel ST)
3 CC180 (95%, ST180, SLV/8561/1380), ST1377 (5%)
9N CC66 (92%, ST66, SLV/517/632/novel ST), ST4666 (8%)
8 CC404 (60%, ST404, SLV/1480, DLV/1268/novel ST), ST53 (40%)
15A CC63 (90%, ST63, DLV/9355), ST3811 (10%)
23A CC42 (73%, ST42, SLV/190/4726/novel ST, DLV/1839/4550), ST338
(27%)
33F CC100 (86%, ST100, SLV/2705), ST1012 (14%)
*SLV single-locus variant; DLV double-locus variants.
22F-ST433 clinical isolates identified a total of 6308 SNPs. After
removal of gaps and putative recombination regions predicted
by BratNextgen, 3886 high-quality SNPs (2212 parsimony
informative sites) were detected from 789,333 sites. A maximum
likelihood phylogeny (un-rooted tree) was constructed. All 22F-
ST433 isolates can be divided into two sub-clusters: clade A
and clade B (Figure 3). In clade A, five isolates that confer
resistance to macrolides (both erythromycin and azithromycin)
are closely related to each other, forming a sub-cluster clade A1.
All isolates in clade B are susceptible to macrolides and other
antibiotics, except for isolate SP194, possessing resistance to
levofloxacin (MIC 4µg/mL) and moxifloxacin (MIC 2µg/mL).
Further comparison of quinolone resistance determinant regions
(QRDR) between quinolone-resistant and sensitive strains found
a non-synonymous mutation on gyrA gene (S81F) only.
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TABLE 2 | Sensitivity and specificity of in silico genomic prediction of antibiotic resistance from short reads for S. pneumoniae isolates.
Antibiotics Isolates susceptible (S) by
phenotype
Isolates resistant (R) by
phenotype
Total
isolates
VME rate
(%)
ME rate
(%)
Sensitivitya
(95% CI)
Specificity
(95% CI)
Genotype S Genotype R Genotype S Genotype R
Erythromycin* 173 0 0 37 210
Clindamycin 208 2 1 21 232
Chloramphenicol 226 0 2 4 232
Tetracycline 202 0 2 28 232
Overall 809 2 5 90 906 0.55 0.22 0.95
(0.90–0.97)
1.00
(0.99–1.00)
*Refers to erythromycin resistance only, without phenotype of clindamycin resistance. VME, very major error (susceptible genotype with resistant phenotype); ME, major error (resistant
genotype with susceptible phenotype). R, resistant; S, sensitive.
aReflects sensitivity for resistance detection.
FIGURE 3 | Phylogenetic analysis of emerging 22F-ST433 isolates from Ontario, Canada between 2009 and 2013. An un-rooted maximum-likelihood tree
based on the core genome with putative recombination sites excluded. Two clades are revealed by the tree: clade A and clade B. Clade A include two sub-clades:
clade A1 (five isolates) and clade A2 (four isolates). All five isolates in clade A1 were resistant to macrolides (shown with red circle at the tip), and one isolate from clade
B was resistant to fluoroquinolones (pink pentagon at the tip). * indicates100% bootstrap support. Each isolate at the tip was labeled as: Serotype-isolate ID-year of
isolation.
Accessory Genome Comparison Discloses
Clade-Specific Genes in 22F
Accessory genomes of clade A and clade B isolates of 22F
were compared, and presence or absence of accessory genes in
each group was determined. A total of 39 genes were unique
to clade A (100% presence in this group, but absent in the
other), while clade B had 8 clade-specific genes (Table 3).
Thirteen genes (combined length of 22,515 bp) unique to clade
A were contiguous to each other (loci SP18.166056.587-610 and
SP18.166056.1991-98) in the genome and encoded for a variety of
bacteriophage proteins. In addition, all clade A strains possessed
Type I restriction system and PhD/Doc toxin-antitoxin (TA)
system in their genomes (PhD-Doc locus is surrounded by Type
I restriction system and integrase). Five (55.6%) clade A isolates
that form clade A1 subclade contained a gene cassette of 5163
bp (loci SP29.152236.85-92) that encode for macrolide resistance
determinants mefE and msrD. The 5.1 kb gene cassette shared
96% similarity withmega (macrolide resistance genetic assembly)
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TABLE 3 | Genome content differences between clade A and clade B of 22F clinical isolates.
Gene clutser
ID
Gene locus position
in draft genome
Gene name % presence in
Clade A (n = 9)
% presence in
Clade B (n = 16)
P value
Z test
Comments
2027 SP18.166056.587 Phage minor tail protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2038 SP18.166056.588 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2006 SP18.166056.589 Phage protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2000 SP18.166056.590 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2030 SP18.166056.591 Phage capsid and scaffold 100.00 0.00 0 Present In Clade A,
absent in Clade B
2009 SP18.166056.592 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2005 SP18.166056.593 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2011 SP18.166056.594 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2031 SP18.166056.595 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2040 SP18.166056.596 Phage capsid and scaffold 100.00 0.00 0 Present In Clade A,
absent in Clade B
2010 SP18.166056.597 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2004 SP18.166056.598 Phage minor capsid protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2037 SP18.166056.599 phage portal protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
1998 SP18.166056.600 Phage terminase, large
subunit
100.00 0.00 0 Present In Clade A,
absent in Clade B
2025 SP18.166056.601 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2042 SP18.166056.603 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2034 SP18.166056.604 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2022 SP18.166056.605 Phage protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2369 SP18.166056.606 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2389 SP18.166056.607 Hypothetical phage protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2017 SP18.166056.608 Phage Holliday junction
resolvase
100.00 0.00 0 Present In Clade A,
absent in Clade B
738 SP18.166056.609 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2021 SP18.166056.610 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
1921 SP18.16605.1991 lysozyme family 100.00 0.00 0 Present In Clade A,
absent in Clade B
2044 SP18.166056.1992 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2043 SP18.166056.1994 putative prophage protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2039 SP18.166056.1995 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
(Continued)
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TABLE 3 | Continued
Gene clutser
ID
Gene locus position
in draft genome
Gene name % presence in
Clade A (n = 9)
% presence in
Clade B (n = 16)
P value
Z test
Comments
2002 SP18.166056.1996 phage tail length tape
measure protein
100.00 0.00 0 Present In Clade A,
absent in Clade B
2024 SP18.166056.1997 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2003 SP18.166056.1998 Phage tail length
tape-measure protein
100.00 0.00 0 Present In Clade A,
absent in Clade B
2051 SP18.166056.519 Type I restriction-modification
system
100.00 0.00 0 Present In Clade A,
absent in Clade B
2012 SP18.166056.520 antitoxin PhD 100.00 0.00 0 Present In Clade A,
absent in Clade B
1999 SP18.166056.521 death on curing protein, Doc
toxin
100.00 0.00 0 Present In Clade A,
absent in Clade B
2016 SP18.166056.522 phage integrase 100.00 0.00 0 Present In Clade A,
absent in Clade B
2007 SP18.166056.858 replication protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2013 SP18.166056.714 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2020 SP18.166056.1278 Phage integrase 100.00 0.00 0 Present In Clade A,
absent in Clade B
2023 SP18.166056.708 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2033 SP18.166056.711 Hypothetical protein 100.00 0.00 0 Present In Clade A,
absent in Clade B
2085 SP21.166057.763 CAAX amino protease I 0.00 100.00 0 Present In Clade B,
absent in Clade A
2138 SP21.166057.764 CAAX amino protease II 0.00 100.00 0 Present In Clade B,
absent in Clade A
2077 SP21.166057.765 Hypothetical protein 0.00 100.00 0 Present In Clade B,
absent in Clade A
2148 SP21.166057.767 UDP-glucose
6-dehydrogenase
0.00 100.00 0 Present In Clade B,
absent in Clade A
2170 SP21.166057.769 Hypothetical protein 0.00 100.00 0 Present In Clade B,
absent in Clade A
2101 SP21.166057.1168 Hypothetical protein 0.00 100.00 0 Present In Clade B,
absent in Clade A
2171 SP21.166057.482 Hypothetical protein 0.00 100.00 0 Present In Clade B,
absent in Clade A
2172 SP21.166057.677 Hypothetical protein 0.00 100.00 0 Present In Clade B,
absent in Clade A
2265 SP29.152236.85 Novel pyridoxal kinase, thiD
family
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2271 SP29.152236.86 ImpB/MucB/SamB family
protein
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2270 SP29.152236.87 Hypothetical protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2276 SP29.152236.88 Hypothetical protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2272 SP29.152236.89 Hypothetical protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
(Continued)
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TABLE 3 | Continued
Gene clutser
ID
Gene locus position
in draft genome
Gene name % presence in
Clade A (n = 9)
% presence in
Clade B (n = 16)
P value
Z test
Comments
1435 SP29.152236.90 marolide-resistance protein
(msrD/mel)
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2283 SP29.152236.91 Macrolide-efflux protein (mefE) 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2268 SP29.152236.92 unknown protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2292 SP30.166058.302 Hypothetical protein 77.78 0.00 0 Overrepresented in
Clade A, absent in
Clade B
2291 SP30.166058.303 Hypothetical protein 77.78 0.00 0 Overrepresented in
Clade A, absent in
Clade B
2296 SP30.166058.304 Hypothetical protein 44.44 0.00 0.00362 Overrepresented in
Clade A, absent in
Clade B
2267 SP29.152236.408 Ribulose-phosphate
3-epimerase (RPE)
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
1510 SP29.152236.409 PTS fructose transporter
subunit IIC
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2273 SP29.152236.410 PTS fructose transporter
subunit IIB
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2275 SP29.152236.411 PTS fructose transporter
subunit IIA
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2280 SP29.152236.412 PTS fructose transporter
subunit IIA
55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2269 SP29.152236.1295 Hypothetical protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2266 SP29.152236.1057 Mobile element protein 44.44 0.00 0.00362 Overrepresented in
Clade A, absent in
Clade B
2282 SP29.152236.1087 Hypothetical protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2284 SP29.152236.732 Hypothetical protein 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2290 SP30.166058.1442 Hypothetical protein 77.78 0.00 0 Overrepresented in
Clade A, absent in
Clade B
2322 SP62.152237.1836 Hypothetical protein 44.44 0.00 0.00362 Overrepresented in
Clade A, absent in
Clade B
1996 SP18.166056.1712 Transposase 55.56 0.00 0.00086 Overrepresented in
Clade A, absent in
Clade B
2035 SP18.166056.1403 Mobile element protein 88.89 0.00 0 Overrepresented in
Clade A, absent in
Clade B
2038 SP18.166056.588 Hypothetical protein 88.89 0.00 0 Overrepresented in
Clade A, absent in
Clade B
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coding sequences upstream of tetM in the Tn2009 transposon
previously described by Del Grosso et al. (2004). All isolates in
clade B contained genes encoding for CAAX amino protease,
putative UDP-glucose 6-dehydrogenase (loci SP21.166057.763-
767) and several hypothetical proteins that clade A
lacked.
DISCUSSION
In a previous study we used the Sanger-sequencing based
MLST method for the molecular typing of S. pneumoniae
isolates from Ontario children (Deng et al., 2015). However,
MLST typing is time consuming and very labor intensive. For
example, to type 100 pneumococcal isolates using seven gene loci,
700 PCR amplifications plus 1400 Sanger sequencing reactions
(forward and reverse direction) are required. Additional repeated
sequencing is often needed for ambiguous bases in a sequence
due to a variety of reasons such as poor DNA quality and
contaminations. Compared to MLST and PFGE, WGS has the
highest discriminatory power and has great potential for large-
scale typing of bacterial isolates (Joensen et al., 2014). In this
surveillance study, we used WGS for rapid determination of
sequence type and antibiotic resistance for IPD isolates submitted
to a public health laboratory. Illumina high-throughput genome
sequencing combined with multiplexing allows rapid sequencing
of hundreds of samples in a short period of time (1–5 days
in rapid run mode). Our results suggest that MLST type could
be accurately predicted from Illumina short reads directly for
S. pneumoniae, provided genome sequences have fairly good
sequencing depth (at least 10 or better). The overall sensitivity
and specificity of genomic prediction of antibiotic resistance
for S. pneumoniae were 95% (95% CI, 90 to 97%), and 100%
(95% CI, 99 to 100%) respectively, compared to standard
susceptibility testing methods. Ninety-seven percent of samples
had complete concordance between genotype and phenotype for
the antimicrobial agents tested, with low rates of VME (0.55%)
and ME (0.22%). These results suggest that WGS prediction of
antibiotic resistance mechanisms acquired through horizontal
gene transfer events was as sensitive and specific as routine
antimicrobial susceptibility assays for pneumococci. However, it
is worth noting that only four antibiotics were tested in this study,
and our observations in pneumococci may not apply to other
bacterial pathogens. In addition, this WGS method is currently
unable to reliably predict some resistance mechanisms due to
point mutations on gene loci. For example, penicillin resistance
among pneumococcal isolates resulting from mutations in
penicillin-binding proteins (PBPs) or non-PBP genes cannot be
predicted. Although, current phenotypic susceptibility assays are
likely to be more reliable for routine testing, WGS methods may
be useful for slow growing organisms, or organisms that cannot
be cultured.
We have detected some VME andME errors when comparing
WGS methods with standard phenotypic susceptibility tests.
Possible explanations for VMEs (genotype-susceptible but
phenotype-resistant) may be sequencing error, alternative
resistance mechanisms that are not reflected in the resistance
gene database and novel resistance mechanisms not previously
described. MEs (phenotypically susceptible isolates that contain
resistance genes) may be the result of suppressed or delayed
gene expression of resistance genes, since expression of a gene
is a complex process that involves the interactions between
repressors, promoters and other regulatory networks.
In our previous study we reported the increase of 22F
prevalence among children (≤ 5 years of age) in Ontario in
the post-PCV13 era (Deng et al., 2015). In the present study a
significant increase in 22F-associated IPD cases was observed in
older adults in Ontario (≥ 50 years old) after the introduction of
PCV13. In 2013, 22F was the most common serotype detected
in IPD among all ages in Ontario, Canada. The emergence of
22F in the post-vaccine era was also reported in other regions
of Canada (Demczuk et al., 2013), and in other countries such
as the USA (Kendall et al., 2016), UK (Pichon et al., 2013),
Germany (van der et al., 2015), and Norway (Steens et al.,
2015). An extensive review of serotype 22F in a MLST database
found that it was broadly distributed in over 25 countries and
the earliest report of IPD caused by 22F was in 1993 (MLST
Databases, 2016). According to the public MLST database,
22F capsular type is mainly associated with the MLST-defined
clonal complex CC433 (over 70%), ST1294 (3.3%) and CC698
(3.1%) (MLST Databases, 2016). Although, 24/25 (96%) Ontario
22F isolates mostly shared identical genotype (ST433), WGS-
based phylogenetic analysis divided the 22F population into two
distinct clusters (clade A and B in Figure 2) that were diverse
in their genomic contents. The discovery of clade-specific gene
sets by comparative genomics suggests the diversification of
22F-ST433 clone. Interestingly, all strains in clade A shared a
23kb-prophage-associated genomic island that clade B lacked.
This chromosomal island comprises 30 genes including lysozyme
genes downstream from the phage minor tail protein gene. To
combat the bacteriophage invasion, clade A strains possessed
anti-phage weaponry of Type-I restriction system that degrades
phage DNA (Loenen et al., 2014) and PhD/Doc TA system
which promotes cell death and limits phage replication within
bacterial populations (Fineran et al., 2009). In addition, clade A1
(5 isolates) acquired macrolide resistance through incorporation
of a 5.1 kb mega gene cassette that encodes for mefE and msrD
resistance genes possibly via horizontal gene transfer. Antibiotic
resistance obtained by 22F might provide selective advantage for
them over other drug-susceptible competitors. In the current
study 19.2% of 22F isolates carried this macrolide-resistant gene
cassette; further dissemination of drug resistance among 22F
should be closely monitored. 22F isolates in clade B possessed
CAAX proteases that may be virulence-related (Firon et al., 2013)
and their exact functions are unknown. One strain in clade
B, isolated in 2013, demonstrated fluoroquinolone resistance
through a de novo gyrA gene mutation (S81F). These gene
differences between distinct clades suggest ongoing evolution and
divergence of 22F clone through genetic recombination possibly
due to rapid adaptation to environmental stress and selection
pressure.
In conclusion, our study suggests that WGS is a valuable
tool for routine molecular typing of pneumococcal isolates in
the clinical laboratory, including antibiotic resistance prediction.
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The emergence of 22F in Ontario, Canada and its population
divergence warrants heightened surveillance. Before routine use
of WGS within clinical laboratories, certain barriers need to be
addressed such as sequencing quality assurance, the need for
automated WGS data analysis tools, and a shortage of qualified
personnel with the necessary skills for data interpretation.
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